

CD274 & PDCD1 Research Grade Reozalimab

Catalog No.	DHJ70121A DHJ70121B	Quantity:	100 µg 1.0 mg
Alternate Names:	Bispecific, IBI 318, IBI-318, IBI318, CAS: 2445259-99-2		
Description:	Research Grade Reozalimab is a bispecific human monoclonal antibody that targets human Programmed cell death 1 ligand 1 (CD274) and Programmed cell death protein 1 (CD279)		
UniProt ID (target):	Q9NZQ7 & Q15116		
Specificity:	Human PD-L1 (CD274) and PD-1 (CD279)		
Concentration:	1.0 mg/ml, lot specific		
Source:	XtenCHO cell line		
Isotype:	Human Ig(G1-kappa_G1-lambda2)		
Formulation:	0.01M PBS buffer, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography		
Applications:	Functional studies		
INN:	Reozalimab		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.